New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2013
04:55 EDTCTRX, CTRX, AET, AET, ESRX, ESRX, AVNR, AVNR, VVUS, VVUS, CVS, CVSPharmaceutical Care Management Association to host a summit
PBM Summit is being held in Las Vegas on March 25-26.
News For CTRX;AET;ESRX;AVNR;VVUS;CVS From The Last 14 Days
Check below for free stories on CTRX;AET;ESRX;AVNR;VVUS;CVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 15, 2014
12:31 EDTAVNROn The Fly: Midday Wrap
Subscribe for More Information
10:36 EDTAVNRHigh option volume stocks
Subscribe for More Information
10:21 EDTAVNRAvanir price target raised to $12.20 on positive Alzheimer data at Cowen
Subscribe for More Information
09:59 EDTCVSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:47 EDTAVNRAvanir price target raised to $17 from $13 at Piper Jaffray
09:35 EDTAVNRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA RSH YHOO GILD TWTR AVNR NFLX BAC C
08:32 EDTAVNRAvanir announces positive Phase II results for AVP-923
Subscribe for More Information
07:24 EDTCVSCVS Health upgraded at Cowen
Subscribe for More Information
06:13 EDTAVNRStocks with implied volatility top IV index mean; AMD AVNR
Subscribe for More Information
06:07 EDTCVSCVS Health upgraded to Outperform from Market Perform at Cowen
September 11, 2014
12:42 EDTVVUSOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
11:29 EDTAVNROptions with increasing implied volatility
Options with increasing implied volatility: VNET AVNR GPRO RAX FTR JDSU PSEC APD SYY GGP
10:59 EDTVVUSArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
10:00 EDTESRXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:01 EDTVVUSOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
05:30 EDTESRXExpress Scripts downgraded to Neutral from Buy at Goldman
Subscribe for More Information
September 9, 2014
12:46 EDTVVUSNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
07:54 EDTAETAetna reaffirms FY14 operating EPS outlook $6.45, consensus $6.58
Subscribe for More Information
September 8, 2014
08:01 EDTCVSCVS Health completes purchase of Navarro Discount Pharmacy
Subscribe for More Information
07:26 EDTCVS, AETMorgan Stanley to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use